Industry Roadmap for Progress on Combating Antimicrobial Resistance

Statement 4 Feb 2026

158th session of the WHO Executive Board (EB158): Draft updated global action plan on antimicrobial resistance

On 4 February 2026, IFPMA delivered a statement on Agenda item 14 on the draft updated global action plan on antimicrobial resistance (AMR) at the 158th session of the WHO Executive Board. We welcome the timely update of the Global Action Plan on AMR (GAP), which provides a unique opportunity to take stock of progress...

Revitalizing the antibiotic pipeline by implementing new R&D pull incentives

With the 2024 UN High-Level Meeting on antimicrobial resistance (AMR) and its political declaration, together with the biennial AMR Ministerial Meeting, the world has set an ambitious agenda to tackle AMR. The next four years offer renewed political momentum to deliver progress ahead of the next UN High-Level Meeting on AMR in 2029. A central priority is creating the necessary policy frameworks that stimulate R&D investment. This brief identifies the key barriers to antibiotic R&D and the policy measures needed to address them. Sustainable, effective pull incentives are urgently required to ensure a reliable pipeline of new antibiotics for patients and health systems. We set out how these incentives should be designed and implemented, guided by a set of core principles to maximize their impact.

Open letter from the innovative pharmaceutical industry to G7 leaders

Ahead of the G7 Leaders’ Summit in Kananaskis from 15 to 17 2025, the global pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Innovative Medicines Canada (IMC), are calling on G7 governments to place health and innovation at the top of their agenda.